Price T Rowe Associates Inc Ultragenyx Pharmaceutical Inc. Transaction History

Price T Rowe Associates Inc

$812 Billion
Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,218,942 shares of RARE stock, worth $115 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,218,942

Previous 2,512,423 28.12%

Holding current value

$115 Million

Previous $106 Million 10.27%

% of portfolio

0.01%

Previous 0.01%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$36.21 - $45.78 $25.6 Million - $32.3 Million	706,519 Added 28.12%	3,218,942 $117 Million
Q4 2024 Feb 14, 2025	SELL	$42.07 - $57.72 $23.4 Million - $32.1 Million	-556,231 Reduced 18.13%	2,512,423 $106 Million
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $3.08 Million - $4.55 Million	76,696 Added 2.56%	3,068,654 $170 Million
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $21.6 Million - $29.8 Million	-576,915 Reduced 16.17%	2,991,958 $123 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $5.17 Million - $6.45 Million	120,175 Added 3.48%	3,568,873 $167 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $9.16 Million - $14.2 Million	288,538 Added 9.13%	3,448,698 $165 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $15.9 Million - $21.2 Million	-454,832 Reduced 12.58%	3,160,160 $113 Million
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $2.66 Million - $3.71 Million	71,231 Added 2.01%	3,614,992 $167 Million
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $20.4 Million - $26.9 Million	-552,627 Reduced 13.49%	3,543,761 $142 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $22.3 Million - $30.6 Million	-660,568 Reduced 13.89%	4,096,388 $190 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $241 Million - $398 Million	-6,023,200 Reduced 55.87%	4,756,956 $197 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $50.6 Million - $94.3 Million	-1,104,630 Reduced 9.29%	10,780,156 $643 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $22.4 Million - $30.4 Million	359,697 Added 3.12%	11,884,786 $863 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $4.87 Million - $5.8 Million	66,043 Added 0.58%	11,525,089 $969 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $35.8 Million - $47.1 Million	459,832 Added 4.18%	11,459,046 $1.03 Billion
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $30.2 Million - $37.9 Million	327,428 Added 3.07%	10,999,214 $1.05 Billion
Q1 2021 May 17, 2021	BUY	$106.9 - $167.73 $128 Million - $201 Million	1,201,294 Added 12.68%	10,671,786 $1.22 Billion
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $799 Million - $1.68 Billion	9,470,492 New	9,470,492 $1.31 Billion

Others Institutions Holding RARE

# of Institutions

336

Shares Held

88.9M

Call Options Held

1.08M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.5B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Ultragenyx Pharmaceutical Inc. Transaction History